Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Minimal residual disease (MRD), where leukemic cell levels are lower than the morphologic detection threshold, is the most important prognostic factor for acute lymphoblastic leukemia (ALL) relapse during first-line chemotherapy treatment and is standard of care in treatment monitoring and decision...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Gökbuget, Nicola, Kantarjian, Hagop M., Brüggemann, Monika, Stein, Anthony S., Bargou, Ralf C., Dombret, Hervé, Fielding, Adele K., Heffner, Leonard, Rigal-Huguet, Françoise, Litzow, Mark, O’Brien, Susan, Zugmaier, Gerhard, Gao, Shan, Nagorsen, Dirk, Forman, Stephen J., Topp, Max S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2019
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849936/
https://ncbi.nlm.nih.gov/pubmed/31648325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000457
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia